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In this Commentary we aim to provide an overview of some specific examples of cancer therapeu-
tics, including targeted approaches using monoclonal antibodies and kinase inhibitors, as well as 
highlight novel approaches for enhancing immunological responses against tumors. We point out 
that a fundamental property of the cancer cell, genomic instability, confounds the targeted therapies 
that aim to induce cell death directly while simultaneously enhancing the potential for immunological 
attack by creating a large number of neoantigens. We argue for combinatorial strategies with agents 
that target tumor cells to release these antigens together with innovative therapies that enhance 






progressed  or  are  progressing  to  the  stage  of  clinical 
application. In this Commentary we aim to give an over-
view  of  some  specific  examples  of  these  novel  thera-
peutics,  in particular  “targeted”  approaches,  including 
monoclonal  antibodies  and  small-molecule  inhibitors 
(SMIs)  of  enzymatic  function,  and  of  approaches  that 
aim  primarily  to  enhance  the  host  immune  responses 
directed  toward  tumors.  We  hope  to  persuade  the 
reader that the insights we have gained into some of the 
factors  imposing  limitations  on  the  efficacy  of  recent 
approaches strongly argue for combinatorial strategies 
including both elements that target tumor cells directly 




Until  recently,  immunotherapeutic  strategies  have 
focused primarily on enhancing  immune effector  func-
tions, founded on the premise that immune stimulation 
may  enable  the  recognition  of  antigenic  determinants 
that  are  expressed  by  the  tumor  but  that  remain  only 
weakly  immunogenic  and  incapable  of  eliciting  pro-
tective  responses  in  the  unmanipulated  host.  Despite 
notable  achievements  in  attempts  to  augment  antitu-
mor  immunity  by  a  variety  of  vaccination  approaches, 
initial  enthusiasm  has  been  tempered  by  the  fact  that 
successes  have  been  anecdotal  and  that  the  gen-
eration  of  measurable  increases  in  antitumor  effector 
responses have not often correlated with significant or 
durable objectively quantifiable clinical responses. This 192  Cancer Cell 12, September 2007 ©2007 Elsevier Inc.lack of clinical success has contributed to  the margin-
alization  of  immunological  approaches  from  the main-
stream of anticancer therapies. We now recognize that 
at  least part of  this  failure of  immune-based strategies 
is attributable  to  the presence of numerous  regulatory 












(e.g.,  Foxp3+CD4+CD25+ cells)  (Nishikawa et  al.,  2005) 
or  suppressive  antigen-presenting  cells  (e.g.,  plasma-
cytoid dendritic  cells, CD11b+Gr1+ myeloid  suppressor 
cells, or Th2-polarized tumor-associated macrophages), 





Together  with  radiotherapy  and  surgery,  conventional 
cytotoxic drugs form a trinity that has provided the basis 










the  bone  marrow.  Rescue  with  autologous  stem  cells 
has demonstrated that dose escalation alone does not 
eradicate the malignancy in many cases, and the lower 
relapse  rates  following  allogeneic  transplantation  for 
hematological malignancies has shown that an associ-
ated  immune-mediated  graft-versus-malignancy  effect 
may  be  equally  important  in  effecting  cure.  Intuitively, 
part of the difficulty inherent in combining conventional 
cytotoxics  with  immune-based  therapies  is  that  the 
damage caused  to  the  lymphohematopoietic compart-
ment will  limit the ability of the host immune system to 











The  development  of  “targeted”  therapies  has  been  a 
major advance in the management of patients with can-
cer. The  term relates  to  increased  target selectivity and 



























mal  case  scenario,  where  the  mutated  kinase  activity 
is both necessary and apparently sufficient for disease 
pathogenesis (a primary case oncogene addiction), per-haps most closely approached  in chronic myeloid  leu-









pre-existent  resistant  clones  (Roche-Lestienne  et  al., 
2003).  Thus,  long-term  use may  be  associated with  a 




next-generation  inhibitors  may  rescue  failing  patients, 
improve primary  response  rates still  further,  and delay 
the development of secondary drug resistance, it is likely 





beyond  early  chronic  phase  to  accelerated  phase  or 
blast  crisis  are  genetically  more  complex  and  exhibit 
lower  response  rates  and  response duration  (O’Dwyer 
et al., 2002). The majority of advanced solid tumors are 
also  genetically  complex.  In  breast  or  colorectal  can-



































it  remains unclear whether mutations of  the  intracellu-
lar  domains  of  membrane  receptor  kinases  affect  the 
response  to  therapeutic  monoclonals.  Thus,  toxicity 
may depend both on differential expression levels, and 
on  the  impact of damaging  the nonmalignant  antigen-
expressing compartment. Some monoclonal antibodies 
may offer the potential for cure, or increased cure rates 
in  combination  with  conventional  chemotherapeutics 
(Feugier et al., 2005). This may be more likely when the 











tive  cancer  stem  cell  compartment,  then  relapse may 





Genomic Instability: The Interface of Targeted 
Therapies and the Immune System
The mechanisms of action of monoclonal antibodies are 
manifold  but  can  be  broadly  categorized  as  direct  or 
indirect. The former may include the blocking of function 
(e.g., hindering ligand binding, increasing internalization 







reported  to  activate  immune  responses  against  tumor 
cells (Burchert et al., 2003). Indeed, SMIs such as ima-
tinib may actually  inhibit  lymphocyte  function  (Dietz et 
al., 2004; Seggewiss et al., 2005). Given our increased 
understanding  of  the  regulatory  circuits  controlling 
immune  activation  it  is  conceivable,  if  not  probable, 
that  the  involvement of  adaptive  immune  responses  is 
constrained by  regulatory mechanisms autonomous  to 
the  effector  T  cell  compartment or mediated  via  other 
regulatory populations. Targeting these inhibitory path-







SMI monotherapies may  provide  unique  opportunities 
for  the  generation  of  antitumor  immunity.  Such muta-




cancers  based  on  analysis  of  cell  lines  or  xenografts, 
provides  unique  insights  into  the  potential  impact  of 
mutagenesis on the generation of novel antigens. Using 
in  silico-based  computer  algorithms  combined  with 
high-throughput post hoc analyses, we found that a sig-
nificant number of candidate tumor neoantigens arise as 









know  antigen  targets.  These  findings  predict  that  the 
ensuing  immune  responses  would  be  patient  specific 

























the past decade  (Parmiani  et  al.,  2007). One perceived 
disadvantage has been the technical complexity of their 
identification and molecular characterization  in  the  indi-
vidual  tumor/patient,  which  imposes  limitations  on  the 
Cancer Cell
Commentaryrapidity of application of such sequence-specific  thera-
pies.  Sequencing  the  entire  genome  of  each  individual 












Amplification  of  these  responses  by  interference  with 
immune regulatory circuits may prove to be an obligate 
element  of  such  strategies.  The  same  approaches  that 
have been applied to target cancer cell survival directly 
are now being applied to target elements of the immune 
system  in  order  to  enhance  antitumor  immunity.  Most 
notable at present are the immunostimulatory monoclo-
nal antibodies. These may  interfere with  the  function of 


















TNF  receptor  family  have  shown  promise  in  preclini-
cal models  (summarized  in Melero et al., 2007). These 
include  anti-CD40  (which  induces  IL-12  production  by 
dendritic  cells  [DC],  thus  enhancing  natural  killer  [NK] 
and  NK  T  cell  activation,  T  helper  type  I  responses, 
and cytotoxic T lymphocyte [CTL] induction, as well as 
directly  inhibiting  tumor  growth)  (French  et  al.,  1999; 
Tong and Stone, 2003), and anti-OX-40, anti-4-1BB, and 













ing  ligand  receptor  (TRAIL-R),  CD40,  and  CD137  (41-










potential  advantage of approaches  relying on  the syn-
ergy of multiple components  is  that  they might  reduce 
the  toxicity  induced  by  higher  doses  of  each  agent 
administered as monotherapy (e.g., immune responses 
may  be  constrained  toward  tumor-related  antigens 
rather than ubiquitous self antigens). The severe toxicity 




2006;  Sheridan,  2006),  although  other  targets  that  do 
not obviate the requirement for TCR signaling in induc-





although  the  pleiotropic  nature  of  their  effects  makes 













comes.  However,  all  such  approaches  are  potentially 
constrained  by  induction  of  regulatory  inhibitory  feed-
back mechanisms  (Ko et  al.,  2005; Biagi  et  al.,  2005). 










in  clinical  development  involves  antibodies  that  block 
CTLA-4,  an  inhibitory  member  of  the  immunoglobulin 
superfamily  of  receptors  (Korman  et  al.,  2006).  Mem-







factors,  and  hence  to  decrease  the  number  of  ligated 
T  cell  receptors  that  are  required  for  a  given  biologi-
cal  response  (Viola  and  Lanzavecchia,  1996).  CTLA-4 
engagement  selectively  blocks  augmentation  of  gene 
regulations  by CD28-mediated  costimulation  but  does 
not  ablate  gene  regulation  induced  by  TCR  triggering 
alone  (Riley et al., 2002). The  function of CTLA-4 as a 
negative regulator of CD28-dependent T cell responses 
is  most  strikingly  demonstrated  by  the  phenotype  of 
CTLA-4  knockout  mice,  which  succumb  to  a  rapidly 
lethal  polyclonal  CD4-dependent  lymphoproliferation 
within 3–4 weeks of birth (Waterhouse et al., 1995; Tivol 
et al., 1995). Antibody-mediated blockade of CTLA-4 is 
particularly  effective  at  enhancing  secondary  immune 
responses, more markedly in CD4+ T cells, and has been 
shown in preclinical models to synergize with a number 
of  other  antitumor  immunotherapies,  while  often  hav-
ing only modest effects as a monotherapy (reviewed in 
Korman  et  al.,  2006).  Furthermore,  early  clinical  stud-
ies  have  shown  that  CTLA-4  blockade  has  activity  as 
a  monotherapy  and,  in  keeping  with  murine  models, 
enhanced activity in combination with some other thera-
pies  in  the  treatment of human malignancies  including 




majority  reversible. Other  inhibitory members of  the  Ig 
superfamily offer further possible targets. For example, 
blockade of  the PD-1:PD-L1 axis has shown consider-
able promise  in  its ability  to  rescue exhausted CD8+ T 
cells in murine models of viral infection and to enhance 
antitumor activity (Barber et al., 2006; Iwai et al., 2005). 
Regulatory  circuits  involving  non-cell-autonomous 
inhibition,  most  notably  regulatory  T  cell  populations, 
offer  a  further possible  therapeutic  target.  The  lack of 




activated  effector  cells.  Denileukin  diftitox  (ONTAK)  is 
a fusion protein designed to direct the cytocidal action 
of  diphtheria  toxin  to  cells  that  overexpress  the  IL-2 







following  denileukin  diftitox  therapy  with  preservation 
of  the CD4+CD25int memory T cell pool  (Dannull  et al., 
2005),  but  possible  depletion  of  CD25+  effector  cells 
with  prolonged  or  repeated  administration  (Barnett  et 
al.,  2005).  Administration  prior  to  vaccination with  DC 
transfected with tumor RNA enhanced tumor  immunity 
as measured by  subsequent  in  vitro  analyses of  cyto-
kine production  in  recall  responses  to  the DC vaccine 
(Dannull et al., 2005). The availability of SMIs selectively 
targeting regulatory T cell function would be a valuable 
addition  to  our  existing  therapeutic  armamentarium. 
Many  SMIs  that  are  directed  at  pathways  involved  in 
peripheral  tolerance  are  in  development  (reviewed  in 
Muller  and Scherle, 2006). These  include  inhibitors of 





fore  suggests  that  conventional  anticancer  therapies 
might  be  viewed  as  immunosupportive  therapies  that 
have  the  potential  to  turn  the  tumor  itself  into  a  form 
of polyvalent  in vivo cellular vaccine, and  that  immune 
checkpoint blockade with or without additional costim-
ulatory  receptor  agonistic  ligation  might  provide  the 
immunological  adjuvant  necessary  to  realize  a  true 
therapeutic  impact  (Figure  1).  Combination  of  regula-
tory  circuit  blockade  with  other  targeted  therapies  is 
particularly attractive, as  the more widespread  toxicity 
to  the  immune  system  that may be  a  consequence  of 
conventional chemotherapy or radiotherapy, and which 
intuitively  might  impact  attempts  to  enhance  immune 
responses,  can be avoided. This  requires  that  the  tar-
geted therapy be capable of  inducing augmentation of 
tumor  antigen  presentation  to  the  immune  system. As 
previously  discussed,  monoclonal  antibodies  are  cer-
tainly  capable  of  initiating  immune  system  activation 




commonly  effected  by many  established  chemothera-
peutics  both  in  vitro  and  in  vivo. While  apoptosis  has 
long been considered as nonimmunogenic or even toler-
izing, a gradual acceptance that not all forms of apop-








CommentaryFigure 1. The Genomic Instability of Cancers Is Important Both in the Evolution of Their Malignant Phenotype and in Providing 












tinib  has been  reported both  to directly  enhance  anti-
gen presentation of mature dendritic cells and to inhibit 
dendritic cell differentiation  from a number of different 
progenitors  (Appel  et  al.,  2005).  In  addition,  it  revers-
ibly inhibits T cell proliferation by interfering with T cell 
receptor  signal  transduction  (Seggewiss  et  al.,  2005). 
Effects  on  antigen  presentation  and  T  cell  responses 
induced by SMI therapies clearly warrant further study, 
and  the  context  in  which  antigen  is  presented  follow-
ing  their  use  (tolerogenic  versus  immunogenic)  needs 
clarification.  Murine  models  allowing  these  issues  to 
be  addressed  are  already  well  established.  In  light  of 
this it is perhaps premature to exclude combinations of 
chemoradiotherapy  and  regulatory  checkpoint  block-
ade. These approaches have shown promise in preclini-
cal models despite concerns that cytotoxic drugs might 
be  detrimental  to  immunotherapies. Cytotoxic  chemo-




et  al.,  2005).  Contributory  factors  also  likely  include 
reduction in regulatory cell function or number (Ghiring-






combinatorial  approaches. Given  the  difficulties  inher-
ent in planning trials that combine multiple new agents, 




Our  hope  is  that  the  opportunities  immune  check-
point blockade offers to enhance responses to antigens 
released  by  tumor  cell  death,  perhaps  augmented  by 
additional manipulations directly promoting the function 
of  lymphocyte  receptors, will allow us  to move  into an 
era where  immunotherapy  emerges  from  the  research 
domain  to  join  the  mainstream  of  oncological  thera-
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